Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

Lung Cancer ◽

10.1016/j.lungcan.2017.07.038 ◽

2017 ◽

Vol 112 ◽

pp. 181-187 ◽

Cited By ~ 20

Author(s):

Martin Reck ◽

Luis Paz-Ares ◽

Paolo Bidoli ◽

Federico Cappuzzo ◽

Shaker Dakhil ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Refractory Disease ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase Iii Study

Download Full-text

Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8055 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8055-8055 ◽

Cited By ~ 3

Author(s):

Luis Paz-Ares ◽

Maurice Perol ◽

Tudor-Eliade Ciuleanu ◽

Ruben Dario Kowalyszyn ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase Iii Study ◽

Nonsquamous Nsclc

Download Full-text

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.lba8006 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. LBA8006-LBA8006 ◽

Cited By ~ 2

Author(s):

Maurice Perol ◽

Tudor-Eliade Ciuleanu ◽

Oscar Arrieta ◽

Kumar Prabhash ◽

Konstantinos N. Syrigos ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology

Annals of Oncology ◽

10.1093/annonc/mdv343.04 ◽

2015 ◽

Vol 26 ◽

pp. vi74 ◽

Cited By ~ 1

Author(s):

P. Bidoli ◽

F. Cappuzzo ◽

A. Favaretto ◽

O. Alabiso ◽

M. Tiseo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Subgroup Analysis ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Lung Cancer ◽

10.1016/j.lungcan.2016.06.019 ◽

2016 ◽

Vol 99 ◽

pp. 94-101 ◽

Cited By ~ 7

Author(s):

Egbert F. Smit ◽

Yi-Long Wu ◽

Radj Gervais ◽

Caicun Zhou ◽

Enriqueta Felip ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Faculty Opinions recommendation of EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718505411.793498028 ◽

2014 ◽

Author(s):

Alexandru Grigorescu

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase Iii Study

Download Full-text

PS13 Late breaking Paclitaxel poliglumex vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): the STELLAR 2 phase III study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)82016-6 ◽

2005 ◽

Vol 3 (4) ◽

pp. 14

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase Iii Study

Download Full-text

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

BMC Cancer ◽

10.1186/1471-2407-10-633 ◽

2010 ◽

Vol 10 (1) ◽

Cited By ~ 22

Author(s):

Athanasios G Pallis ◽

Sophia Agelaki ◽

Athina Agelidou ◽

Ioannis Varthalitis ◽

Kostas Syrigos ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Single Agent ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase Iii Study

Download Full-text

Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.9079 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9079-9079 ◽

Cited By ~ 3

Author(s):

Martin Reck ◽

Luis G. Paz-Ares ◽

Paolo Bidoli ◽

Federico Cappuzzo ◽

Shaker R. Dakhil ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Subgroup Analysis ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Second Line ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study

Download Full-text

O-099 XYOTAX™ vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): The STELLAR 2 phase III study

Lung Cancer ◽

10.1016/s0169-5002(05)80233-8 ◽

2005 ◽

Vol 49 ◽

pp. S35 ◽

Cited By ~ 10

Author(s):

P. Bonomi ◽

L. Paz-Ares ◽

C. Langer ◽

M. O'Brien ◽

R. Gervais ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase Iii Study

Download Full-text

Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdx091.040 ◽

2017 ◽

Vol 28 ◽

pp. ii43

Author(s):

M. Reck ◽

L. Paz-Ares ◽

D. Moro-Sibilot ◽

F.A. Shepherd ◽

F. Cappuzzo ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Study ◽

Line Chemotherapy

Download Full-text